clinical trial · NCT06979674
Study of ESG406 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd·phase1·recruiting·n = 556
Locally Advanced/Metastatic Solid TumorsESG406
brief summary
This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.
started
Jun 4, 2025
primary completion
Apr 1, 2028
completion
Jun 1, 2028
last updated
Sep 12, 2025
official title
An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG406 in Subjects With Locally Advanced/Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol